Cervical cancer (CC) remains a leading cause of cancer-related mortality among women worldwide, particularly in low-resource settings. Despite the availability of screening tools such as Pap smears and HPV DNA testing, limitations in sensitivity and specificity hinder early detection. The emergence of novel biomarkers—spanning genomics, transcriptomics, proteomics, and metabolomics—offers promising avenues for improving diagnostic accuracy, prognostic assessment, and therapeutic monitoring. This review explores the methodologies and technologies involved in the detection of novel 

Cervical cancer is primarily caused by persistent infection with high-risk human papillomavirus (HPV) genotypes, notably HPV-16 and HPV-18 [1]. Traditional screening methods, including cytology and HPV DNA testing, have significantly reduced incidence rates in developed countries. However, these methods often fail to detect glandular lesions and early-stage malignancies [2]. The identification of novel biomarkers—molecular signatures that indicate disease presence or progression—has become a focal point in cervical cancer research. Biomarkers can be derived from blood, urine, cervical-vaginal fluid, or tissue samples and may include proteins, nucleic acids, metabolites, or epigenetic modifications [3].

2.1. High-Risk HPV Infection

Persistent infection with high-risk HPV types—especially HPV-16 and HPV-18—is the primary driver of cervical carcinogenesis. These viruses produce E6 and E7 oncoproteins that inactivate tumor suppressors p53 and Rb, leading to genomic instability and uncontrolled cell proliferation. While HPV DNA testing is widely used, it cannot distinguish between transient infection and malignant transformation. Therefore, downstream molecular changes such as p16INK4a overexpression are more reliable biomarkers. Understanding HPV’s role in disrupting cellular pathways like apoptosis, immune evasion, and angiogenesis helps researchers identify biomarkers that reflect disease progression rather than mere infection. This foundational knowledge guides the search for molecular indicators that can improve early detection and risk stratification [3].

2.2. Genomic Studies 

Genomic technologies such as GWAS and NGS have transformed biomarker discovery in cervical cancer. These methods identify mutations, SNPs, and chromosomal aberrations linked to cancer susceptibility. Commonly altered genes include PIK3CA, TP53, and HLA loci. NGS enables high-resolution mapping of tumor genomes, uncovering driver mutations and gene fusions that may serve as predictive biomarkers. Genomic data also support personalized medicine by stratifying patients based on molecular profiles. Integration with clinical outcomes enhances the development of risk models and targeted therapies. Genomic biomarkers are increasingly used for early detection, prognosis, and monitoring treatment response, although clinical translation requires rigorous validation [4].

2.3. Transcriptomic Profiling 

Transcriptomic analysis investigates RNA molecules—including mRNAs, microRNAs, lncRNAs, and circRNAs—to identify expression changes associated with cervical cancer. Dysregulated transcripts such as HPV E6/E7 mRNA and miR-9 are linked to early-stage disease and prognosis. RNA-seq and microarrays are commonly used to detect these changes. Non-coding RNAs regulate gene expression and are stable in body fluids, making them ideal for non-invasive diagnostics. Transcriptomic biomarkers offer insights into tumor biology and can complement genomic and proteomic data for comprehensive disease profiling. Their dynamic nature allows for real-time monitoring of disease progression and therapeutic response [5].

2.4. Proteomic Analysis

Proteomics focuses on identifying and quantifying proteins that are differentially expressed in cervical cancer. Techniques like mass spectrometry and immunoassays reveal biomarkers such as p16INK4a, Ki-67, SCC-Ag, and CYFRA21-1. These proteins are associated with cell proliferation, tumor burden, and disease progression. Proteomic studies also explore post-translational modifications, which affect protein function and may serve as additional biomarkers. Proteomic data enhance diagnostic accuracy and support clinical decision-making, especially when integrated with transcriptomic findings. Advances in quantitative proteomics have improved sensitivity and reproducibility, paving the way for multiplex assays and personalized diagnostics [6].

2.5. Metabolomic Screening

Metabolomics analyzes small molecules and metabolites that reflect cellular metabolism. Cancer cells undergo metabolic reprogramming, resulting in altered levels of lactate, choline, and glutamine. Techniques like NMR and MS detect these changes in tissues, blood, and cervical-vaginal fluid. Metabolomic biomarkers are sensitive indicators of tumor activity and can be used for early detection, prognosis, and treatment monitoring. Integration with other omics data provides a holistic view of tumor biology and enhances biomarker discovery. Despite challenges in standardization and variability, metabolomics holds promise for rapid, non-invasive, and cost-effective diagnostics [7].

2.6. Epigenetic Markers

Epigenetic modifications—such as DNA methylation and histone changes—play a crucial role in cervical carcinogenesis. Genes like SOX1, EPB41L3, and JAM3 show hypermethylation in cervical neoplasia. These changes are stable and detectable in tissue and fluid samples, making them ideal for screening and risk stratification. Epigenetic biomarkers can distinguish between benign and malignant lesions and offer insights into gene regulation. Their non-invasive detectability and high specificity make them valuable tools in clinical diagnostics. Ongoing research aims to develop methylation panels for population-wide screening and personalized risk assessment [8].

2.7. Sample Sources 

Biomarkers can be extracted from various biological samples, including cervical tissue, cervical-vaginal fluid, blood, and urine. Non-invasive sources like urine and cervical fluid are preferred for screening, while tissue biopsies offer high specificity for staging and validation. The choice of sample affects biomarker sensitivity, reproducibility, and clinical applicability. Advances in liquid biopsy technologies have expanded the potential for detecting circulating biomarkers such as ctDNA and exosomes, improving patient comfort and compliance. Sample accessibility and stability are key considerations in biomarker development [9].

2.8. Multi-Omics Integration 

Combining data from genomics, transcriptomics, proteomics, and metabolomics enhances biomarker discovery. Multi-omics approaches reveal complex molecular interactions and improve diagnostic accuracy. Integrated analyses help identify biomarker panels with higher sensitivity and specificity than single markers. This strategy supports personalized medicine by tailoring diagnostics and treatments to individual molecular profiles. Multi-omics integration also facilitates disease subtyping and prediction of therapeutic response, advancing precision oncology. Despite computational challenges, it remains a powerful tool for translational research [10].

2.9. Bioinformatics Tools 

Bioinformatics platforms like STRING, Cytoscape, and GEO2R are essential for analyzing large omics datasets. These tools identify differentially expressed genes, construct molecular networks, and prioritize biomarker candidates. Functional enrichment analyses (e.g., GO and KEGG) help interpret biological significance. Bioinformatics accelerates biomarker discovery by enabling high-throughput data processing and visualization. It also supports reproducibility and cross-study comparisons, making it indispensable in modern cancer research. Integration with machine learning further enhances predictive modeling [11].

2.10. Machine Learning Algorithms 

Machine learning models—such as random forest, support vector machines, and neural networks—enhance biomarker discovery and clinical prediction. These algorithms analyze complex datasets to classify patients, predict outcomes, and identify biomarker patterns. ML improves diagnostic accuracy and supports decision-making in personalized medicine. It also enables real-time analysis of patient data, facilitating adaptive treatment strategies. As omics data grow, ML will play an increasingly vital role in translating biomarkers into clinical practice. Its ability to uncover hidden patterns makes it a cornerstone of modern oncology research [12].

3.Detection Technologie:

3.1. Next-Generation Sequencing (NGS)

NGS enables high-throughput analysis of genomic and transcriptomic alterations in cervical cancer. It identifies mutations, copy number variations, and gene fusions with high sensitivity. NGS is instrumental in discovering novel biomarkers such as HPV integration sites and oncogenic mutations in PIK3CA and TP53. It also supports personalized medicine by profiling tumor heterogeneity and guiding targeted therapies. NGS platforms like Illumina and Ion Torrent are widely used in research and clinical diagnostics. Despite its power, challenges include cost, data complexity, and the need for bioinformatics expertise [12].

3.1. Next-Generation Sequencing (NGS)

NGS enables high-throughput analysis of genomic and transcriptomic alterations in cervical cancer. It identifies mutations, copy number variations, and gene fusions with high sensitivity. NGS is instrumental in discovering novel biomarkers such as HPV integration sites and oncogenic mutations in PIK3CA and TP53. It also supports personalized medicine by profiling tumor heterogeneity and guiding targeted therapies. NGS platforms like Illumina and Ion Torrent are widely used in research and clinical diagnostics. Despite its power, challenges include cost, data complexity, and the need for bioinformatics expertise [12].

3.2. Microarray Technology 

Microarrays allow simultaneous analysis of thousands of genes or transcripts. They are used to detect gene expression changes, SNPs, and epigenetic modifications. In cervical cancer, microarrays have identified dysregulated genes and miRNAs linked to progression and prognosis. This technology is cost-effective and suitable for large-scale screening. However, it has lower resolution compared to NGS and may miss rare variants. Microarrays remain valuable for biomarker discovery and validation in population studies [13].

3.3. Mass Spectrometry (MS)

MS is a cornerstone of proteomic and metabolomic biomarker detection. It identifies and quantifies proteins and metabolites in cervical tissue, blood, or cervical-vaginal fluid. MS-based techniques like MALDI-TOF and LC-MS/MS have revealed biomarkers such as SCC-Ag, CYFRA21-1, and VEGF. MS also detects post-translational modifications, enhancing biomarker specificity. Its high sensitivity and multiplexing capability make it ideal for clinical translation. Limitations include sample preparation complexity and instrument cost [14].

3.4. Immunohistochemistry (IHC) [15]

IHC visualizes protein biomarkers in tissue sections using labeled antibodies. It is widely used to detect p16INK4a, Ki-67, and other markers in cervical biopsies. IHC provides spatial context and is essential for histopathological diagnosis. Dual staining (e.g., p16/Ki-67) improves specificity for CIN2+ lesions. While semi-quantitative, IHC is reproducible and accessible in clinical settings. It complements molecular assays and supports biomarker validation [15].

3.5. Quantitative PCR (qPCR) and RT-PCR 

qPCR and RT-PCR are gold standards for detecting DNA and RNA biomarkers. They quantify HPV DNA, E6/E7 mRNA, and miRNAs with high sensitivity. These techniques are fast, cost-effective, and suitable for routine diagnostics. qPCR is used in HPV genotyping and methylation analysis, while RT-PCR profiles transcriptomic changes. Their accuracy depends on primer design and sample quality. qPCR-based assays are being adapted for point-of-care testing [16].

3.6. Enzyme-Linked Immunosorbent Assay (ELISA) 

ELISA quantifies protein biomarkers in serum, plasma, or cervical fluid. It is used to measure SCC-Ag, CA-125, and CYFRA21-1 levels for diagnosis and monitoring. ELISA is simple, scalable, and suitable for population screening. It supports longitudinal studies and therapeutic response tracking. However, it may lack specificity if biomarkers overlap with other conditions. Multiplex ELISA platforms improve throughput and diagnostic accuracy [17].

3.7. Liquid Biopsy 

Liquid biopsy involves non-invasive sampling of blood, urine, or cervical fluid to detect circulating biomarkers. It identifies ctDNA, exosomes, and cell-free RNA linked to cervical cancer. Liquid biopsy enables early detection, prognosis, and treatment monitoring. It is especially useful in low-resource settings and for patients unable to undergo invasive procedures. Advances in microfluidics and nanotechnology enhance sensitivity. Validation and standardization are ongoing challenges [18].

3.8. Digital Pathology & AI 

Digital pathology uses high-resolution imaging and AI algorithms to analyze tissue samples. It automates biomarker scoring and reduces observer variability. AI models detect patterns in IHC-stained slides, improving CIN grading and cancer diagnosis. Integration with electronic health records supports clinical decision-making. Digital pathology enhances reproducibility and scalability in biomarker validation. Regulatory approval and infrastructure remain barriers to widespread adoption [19].

3.9. Biosensors & Point-of-Care Devices

 Biosensors detect biomarkers using electrochemical, optical, or piezoelectric signals. Devices targeting p16INK4a and HPV DNA offer rapid, low-cost diagnostics. Point-of-care platforms are ideal for rural and underserved areas. They enable real-time screening and reduce diagnostic delays. Advances in nanomaterials and microfluidics improve sensitivity and portability. Biosensors are being integrated into mobile health systems for remote monitoring [20].

3.10. Fluorescence in Situ Hybridization (FISH) 

FISH detects chromosomal abnormalities and gene amplifications in cervical cancer cells. It is used to identify HPV integration sites and telomerase RNA gene (TERC) alterations. FISH provides spatial resolution and complements genomic assays. It is valuable for confirming molecular findings and guiding treatment decisions. Limitations include technical complexity and cost. FISH remains a robust tool for cytogenetic biomarker analysis [21].

4.1. Analytical Validation 

Analytical validation ensures that biomarker assays are accurate, reproducible, and sensitive across different platforms and laboratories. Parameters such as limit of detection, specificity, linearity, and precision are rigorously tested. For cervical cancer biomarkers like p16INK4a and HPV E6/E7 mRNA, validation involves comparing assay performance across sample types (e.g., tissue vs. fluid) and conditions. Standardized protocols and quality control measures are essential to minimize variability and ensure reliability in clinical settings [21].

4.2. Clinical Validation 

Clinical validation confirms that a biomarker correlates with disease presence, progression, or response to treatment. This involves testing in diverse patient populations and comparing biomarker levels with clinical outcomes. For example, methylated DNA markers and miRNAs have shown strong associations with CIN2+ and cervical cancer stages. Large-scale studies are needed to establish sensitivity, specificity, and predictive value before clinical adoption [22].

4.3. Population-Based Studies 

Validation across different populations ensures biomarker applicability in varied genetic, environmental, and socioeconomic contexts. Studies in low- and middle-income countries (LMICs) are crucial, as cervical cancer burden is highest there. Biomarkers like SCC-Ag and VEGF must be tested in multi-ethnic cohorts to confirm universal relevance. Population-based validation also helps identify subgroup-specific markers and refine screening strategies [23].

4.4. Regulatory Approval

For clinical use, biomarkers must meet regulatory standards set by agencies like the FDA or EMA. This includes demonstrating analytical and clinical validity, as well as clinical utility. Regulatory approval involves rigorous documentation, reproducibility across labs, and evidence of improved patient outcomes. Biomarkers like p16/Ki-67 dual staining have undergone such scrutiny and are now used in clinical diagnostics [24].

4.5. Biomarker Panels 

Combining multiple biomarkers into panels enhances diagnostic accuracy and reduces false positives. Panels integrating HPV DNA, methylation markers, and protein biomarkers outperform single tests. For example, combining p16INK4a, Ki-67, and miR-9 improves CIN2+ detection. Validation of panels involves assessing synergistic performance, cost-effectiveness, and ease of implementation in clinical workflows [25].

4.6. Longitudinal Studies 

Long-term studies track biomarker levels over time to assess their prognostic value and utility in monitoring treatment response. For cervical cancer, markers like SCC-Ag and CYFRA21-1 are monitored post-treatment to detect recurrence. Longitudinal validation helps determine biomarker stability, predictive timelines, and thresholds for clinical action. These studies are vital for integrating biomarkers into follow-up protocols [26].

4.7. Cost-Effectiveness Analysis

Economic evaluation determines whether biomarker-based tests offer value compared to existing methods. In LMICs, affordability and scalability are critical. Cost-effectiveness studies compare biomarker panels with Pap smears and HPV testing, factoring in diagnostic accuracy, infrastructure needs, and patient outcomes. Biomarkers that reduce unnecessary procedures and improve early detection are favored for clinical translation [27].

4.8. Clinical Utility Assessment 

Clinical utility refers to a biomarker’s ability to improve patient management decisions. This includes guiding treatment choices, reducing overtreatment, and enhancing screening efficiency. For instance, p16/Ki-67 dual staining helps triage HPV-positive women, minimizing unnecessary colposcopies. Utility assessment involves randomized trials and real-world implementation studies to confirm impact on care pathways [28].

4.9. Integration into Guidelines]

Validated biomarkers must be incorporated into clinical guidelines to ensure widespread adoption. Organizations like WHO and ASCCP evaluate evidence and recommend biomarkers for screening and triage. Integration requires consensus on cutoff values, testing protocols, and interpretation standards. Biomarkers like HPV E6/E7 mRNA and methylation panels are being considered for inclusion in updated cervical cancer screening algorithms [29].

4.10. Real-World Implementation

Successful translation involves deploying biomarker tests in routine clinical practice. This includes training personnel, establishing infrastructure, and ensuring supply chain logistics. Pilot programs in LMICs have tested point-of-care devices for HPV and methylation markers. Real-world implementation studies assess feasibility, patient acceptability, and health system impact, bridging the gap between research and practice [30].

5.1. p16INK4a/Ki-67 Dual Staining 

The p16INK4a/Ki-67 dual staining technique is a widely accepted biomarker strategy for identifying high-grade cervical intraepithelial neoplasia (CIN2+). p16INK4a is a cyclin-dependent kinase inhibitor that becomes overexpressed in HPV-transformed cells due to E7-mediated inactivation of the retinoblastoma protein (pRb). Ki-67, on the other hand, is a nuclear protein that marks proliferating cells. When both markers are co-expressed in the same cell, it strongly suggests dysplastic transformation. This dual staining method significantly improves diagnostic specificity and sensitivity compared to HPV DNA testing alone. It is particularly useful in triaging HPV-positive women, helping reduce unnecessary colposcopies and overtreatment. The test is performed via immunocytochemistry on cervical smears or biopsies and is already integrated into clinical guidelines in many countries. Its utility in low-resource settings is also being explored due to its cost-effectiveness and ease of interpretation. Overall, p16/Ki-67 remains a cornerstone biomarker in cervical cancer screening and early diagnosis [31].

5.2. HPV E6/E7 mRNA 

HPV E6/E7 mRNA detection is a highly specific biomarker for identifying transforming HPV infections. Unlike HPV DNA, which may persist without causing disease, E6 and E7 mRNA transcripts indicate active viral oncogene expression. These oncoproteins disrupt tumor suppressors p53 and Rb, leading to uncontrolled cell proliferation and genomic instability. Detection of E6/E7 mRNA is more predictive of disease progression and is particularly useful in distinguishing transient infections from those likely to develop into cervical cancer. It is also valuable for monitoring treatment response and recurrence. E6/E7 mRNA assays are performed using reverse transcription PCR (RT-PCR) and are compatible with liquid-based cytology samples. Studies have shown that E6/E7 mRNA testing improves triage accuracy for HPV-positive women and may reduce unnecessary follow-up procedures. Its integration into screening protocols is growing, especially in settings where HPV DNA testing alone lacks specificity [32].

5.3. DNA Methylation Markers (SOX1, EPB41L3, JAM3) 

DNA methylation biomarkers such as SOX1, EPB41L3, and JAM3 are emerging as powerful tools for cervical cancer screening. These genes are typically silenced through hypermethylation in precancerous and cancerous cervical lesions. Methylation changes are stable, reproducible, and detectable in various sample types including cervical fluid, urine, and tissue biopsies. Methylation assays offer high sensitivity and specificity for CIN2+ lesions and are particularly useful in triaging HPV-positive women. They can be performed using quantitative methylation-specific PCR (qMSP), which is compatible with self-collected samples. This makes them ideal for population-wide screening, especially in low-resource settings. Methylation panels combining multiple genes have shown superior performance compared to single markers. Additionally, methylation biomarkers may help predict disease progression and guide personalized treatment strategies. Their non-invasive nature and robustness make them attractive candidates for integration into routine cervical cancer screening programs [33].

5.4. MicroRNAs (miR-9, miR-21, miR-200c) 

MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression post-transcriptionally and are frequently dysregulated in cervical cancer. miR-9 has been associated with poor prognosis and tumor aggressiveness, while miR-21 and miR-200c are linked to cell proliferation, invasion, and metastasis. These miRNAs are stable in body fluids such as serum and cervical-vaginal fluid, making them suitable for non-invasive diagnostics. Their expression profiles can differentiate between benign, precancerous, and malignant lesions. miRNA panels are being developed to improve diagnostic accuracy and predict recurrence risk. Detection is typically performed using RT-qPCR or microarray platforms. miRNAs also hold promise as therapeutic targets due to their role in regulating oncogenic pathways. Ongoing research is exploring their integration into personalized screening and monitoring strategies. Their accessibility, stability, and biological relevance make miRNAs one of the most promising classes of biomarkers in cervical cancer [34].

5.5. Macrophage Colony-Stimulating Factor (M-CSF) 

M-CSF is a cytokine involved in the regulation of macrophage differentiation and immune response. Elevated serum levels of M-CSF have been observed in cervical cancer patients and correlate with tumor stage and lymph node involvement. M-CSF promotes angiogenesis and tumor progression by modulating the tumor microenvironment. It is a potential biomarker for diagnosis, prognosis, and monitoring treatment response. M-CSF can be measured using ELISA assays, making it suitable for routine clinical use. When combined with other markers such as VEGF, its diagnostic accuracy improves significantly. M-CSF may also serve as a therapeutic target, as blocking its signaling pathway could inhibit tumor growth and metastasis. Its role in immune modulation makes it particularly relevant in the context of immunotherapy. Further validation in large cohorts is needed, but current evidence supports its inclusion in biomarker panels for cervical cancer [35].

5.6. Vascular Endothelial Growth Factor (VEGF) 

VEGF is a key regulator of angiogenesis and is overexpressed in cervical cancer tissues. Its serum levels correlate with tumor size, stage, and lymph node metastasis. VEGF promotes vascular permeability and endothelial cell proliferation, facilitating tumor growth and dissemination. It is a valuable prognostic biomarker and may guide anti-angiogenic therapies. VEGF levels can be measured using ELISA or immunohistochemistry, making it accessible for clinical use. Studies have shown that high VEGF expression is associated with poor survival and increased recurrence risk. VEGF inhibitors are being explored as therapeutic options in cervical cancer, and VEGF levels may help identify patients who would benefit from such treatments. Its integration into biomarker panels enhances diagnostic precision and supports personalized treatment planning. VEGF’s role in tumor biology and its detectability in serum make it a promising candidate for routine monitoring [36].

5.7. Alpha-Actinin-4 (ACTN4) 

ACTN4 is a cytoskeletal protein involved in cell motility and invasion. It is found in cervical-vaginal fluid and has been proposed as a biomarker for self-screening of cervical (pre)cancer. Elevated ACTN4 levels are associated with high-grade lesions and invasive cervical cancer. Its detection in non-invasive samples makes it ideal for point-of-care diagnostics and home-based screening. ACTN4 assays can be performed using immunoassays or mass spectrometry. Its specificity and accessibility offer potential for improving early detection, especially in underserved populations. ACTN4 may also play a role in epithelial-mesenchymal transition (EMT), contributing to tumor progression. Ongoing research is validating its utility in large-scale screening programs. If successfully implemented, ACTN4-based tests could revolutionize cervical cancer screening by increasing coverage and reducing barriers to care [37].

5.8. Squalene Epoxidase (SQLE) 

SQLE is an enzyme involved in cholesterol biosynthesis and is overexpressed in cervical cancer. It promotes epithelial-mesenchymal transition (EMT), proliferation, and immune evasion. High SQLE expression is associated with poor prognosis and shorter overall survival. SQLE influences tumor metabolism and may affect chemosensitivity. It is detectable via RNA sequencing and immunohistochemistry. SQLE’s role in regulating cholesterol homeostasis links it to tumor growth and metastasis. It also interacts with immune checkpoints, suggesting potential for combination therapies. SQLE methylation status has been correlated with clinical outcomes, adding another layer of biomarker utility. Targeting SQLE may offer new therapeutic avenues, especially in resistant or recurrent cases. Its multifaceted role in tumor biology makes it a compelling candidate for diagnostic, prognostic, and therapeutic applications in cervical cancer [38].

5.9. Circulating Tumor DNA (ctDNA) 

ctDNA consists of fragmented DNA released by tumor cells into the bloodstream. It carries tumor-specific mutations, methylation patterns, and copy number alterations. ctDNA enables non-invasive monitoring of tumor burden, recurrence, and treatment response. It is particularly useful in detecting minimal residual disease and guiding adaptive therapy. ctDNA assays use techniques like digital PCR and NGS for high sensitivity. In cervical cancer, ctDNA has shown promise in identifying HPV integration sites and oncogenic mutations. Its dynamic nature allows real-time tracking of disease progression. ctDNA is being integrated into personalized oncology workflows and may complement traditional imaging and biopsy methods. Despite challenges in standardization, ctDNA represents a transformative biomarker for precision medicine in cervical cancer [39].

5.10. Autoantibodies Against Tumor Antigens 

Autoantibodies are produced by the immune system in response to tumor-associated antigens. Their presence in serum can serve as an early warning signal for cervical cancer. Panels of autoantibodies have been developed to differentiate malignant from benign conditions. These biomarkers are stable, accessible, and suitable for population screening. Autoantibody profiling may also predict disease progression and recurrence. Detection is typically performed using protein microarrays or ELISA. Autoantibodies complement other biomarkers and may enhance diagnostic accuracy when used in combination. Their role in immune surveillance makes them relevant in immunotherapy contexts. Ongoing research is refining autoantibody panels for clinical use. If validated, they could offer a low-cost, non-invasive tool for early detection and monitoring [40].

6.1. Diagnostic Biomarkers

Diagnostic biomarkers help identify the presence of cervical cancer or precancerous lesions. These include HPV DNA, p16INK4a, and Ki-67, which are commonly used in cytology and histology. p16INK4a is overexpressed in HPV-transformed cells, while Ki-67 marks active proliferation. Their co-expression improves specificity for CIN2+ lesions. Diagnostic biomarkers are essential for early detection and screening, especially in low-resource settings. They can be measured in cervical smears, biopsies, or body fluids, and are often integrated into routine screening protocols to improve accuracy and reduce false positives [41].

6.2. Prognostic Biomarkers 

Prognostic biomarkers predict the likely course of cervical cancer, including recurrence risk and overall survival. Examples include VEGF, miR-9, and methylated DNA markers like SOX1. High VEGF levels correlate with poor prognosis due to enhanced angiogenesis. Prognostic biomarkers guide treatment intensity and follow-up strategies. They are especially useful in advanced-stage disease to assess aggressiveness and inform therapeutic decisions. These markers are validated through longitudinal studies and are increasingly used in personalized oncology [42].

6.3. Predictive Biomarkers 

Predictive biomarkers indicate how a patient will respond to a specific therapy. For cervical cancer, PD-L1 expression predicts response to immune checkpoint inhibitors, while HPV E6/E7 mRNA levels may forecast sensitivity to radiotherapy. These biomarkers are crucial for tailoring treatment plans and avoiding ineffective therapies. Predictive markers are often assessed before initiating treatment and are used to stratify patients in clinical trials. Their role in precision medicine is expanding, especially with the rise of targeted and immunotherapies [43].

6.4. Genomic Biomarkers 

Genomic biomarkers include mutations, SNPs, and chromosomal aberrations identified through technologies like NGS and GWAS. Commonly altered genes in cervical cancer include PIK3CA, TP53, and HLA loci. These biomarkers help assess genetic susceptibility, tumor behavior, and potential therapeutic targets. Genomic profiling supports personalized treatment and risk stratification. It also aids in identifying hereditary cancer syndromes and guiding genetic counseling. Genomic biomarkers are foundational in multi-omics approaches to cervical cancer research [44].

6.5. Transcriptomic Biomarkers 

Transcriptomic biomarkers involve changes in RNA expression, including mRNAs, microRNAs, lncRNAs, and circRNAs. Dysregulated transcripts such as HPV E6/E7 mRNA and miR-21 are linked to disease progression and prognosis. These biomarkers are detected using RNA-seq or microarrays and are often stable in body fluids, making them suitable for non-invasive testing. Transcriptomic profiling reveals tumor biology and regulatory networks, offering insights into mechanisms of carcinogenesis and potential therapeutic targets [45].

6.6. Proteomic Biomarkers 

Proteomic biomarkers are proteins whose expression levels or modifications are altered in cervical cancer. Examples include p16INK4a, SCC-Ag, CYFRA21-1, and Ki-67. These markers are detected using mass spectrometry, ELISA, or immunohistochemistry. Proteomic biomarkers are used for diagnosis, prognosis, and monitoring treatment response. They also help identify pathways involved in tumor progression and resistance. Advances in quantitative proteomics have improved sensitivity and reproducibility, making these biomarkers more clinically viable [46].

6.7. Metabolomic Biomarkers 

Metabolomic biomarkers are small molecules reflecting metabolic changes in cancer cells. Altered levels of lactate, choline, and glutamine are commonly observed in cervical cancer. These biomarkers are detected using NMR or MS and provide insights into tumor metabolism and microenvironment. Metabolomic profiling supports early detection, prognosis, and therapeutic monitoring. It also complements other omics data to build comprehensive biomarker panels. Despite challenges in standardization, metabolomics holds promise for rapid, non-invasive diagnostics [47].

6.8. Epigenetic Biomarkers 

Epigenetic biomarkers involve changes in DNA methylation, histone modifications, and chromatin remodeling. Hypermethylation of genes like SOX1, EPB41L3, and JAM3 is associated with cervical neoplasia. These markers are stable and detectable in various sample types, including cervical fluid and urine. Epigenetic biomarkers are useful for screening, risk stratification, and predicting disease progression. They are often assessed using methylation-specific PCR and are being integrated into multi-gene panels for clinical use [48].

6.9. Imaging-Based Biomarkers

Imaging biomarkers are derived from radiological techniques like MRI, CT, and ultrasound. They help assess tumor size, vascularity, and lymph node involvement. Radiomics—using AI to analyze imaging data—can identify patterns predictive of treatment response and prognosis. Imaging biomarkers complement molecular data and are essential for staging and monitoring. Their integration with digital pathology and machine learning enhances diagnostic precision and supports personalized care [49].

6.10. Circulating Biomarkers

Circulating biomarkers include ctDNA, exosomes, and cell-free RNA found in blood or cervical fluid. These markers enable non-invasive monitoring of tumor burden, recurrence, and treatment response. ctDNA carries tumor-specific mutations and methylation patterns, while exosomes contain proteins and RNAs reflective of tumor activity. Circulating biomarkers are ideal for longitudinal studies and adaptive therapy strategies. Their development is advancing liquid biopsy technologies for cervical cancer management [50].

7.1. Biomarker Discovery via Omics Technologies

The first step in detecting cervical cancer biomarkers involves high-throughput omics technologies—genomics, transcriptomics, proteomics, and metabolomics. These platforms allow researchers to analyze thousands of molecular features simultaneously. Genomic studies identify mutations and SNPs linked to cervical carcinogenesis, while transcriptomic profiling reveals dysregulated RNAs such as HPV E6/E7 mRNA and microRNAs like miR-21. Proteomic approaches detect altered protein [removed]e.g., p16INK4a, SCC-Ag), and metabolomics uncovers shifts in metabolites like lactate and choline. These technologies generate vast datasets that require bioinformatics tools to filter and prioritize potential biomarkers. Integration of multi-omics data enhances the reliability and biological relevance of candidate markers. This discovery phase is crucial for identifying molecular signatures that reflect disease onset, progression, and therapeutic response, laying the foundation for subsequent validation and clinical translation [51].

7.2. Sample Collection and Preparation 

Biomarker detection begins with careful sample collection from cervical tissue, cervical-vaginal fluid, blood, or urine. The choice of sample affects sensitivity, specificity, and feasibility. Cervical smears and biopsies are ideal for tissue-based markers like p16INK4a, while blood and urine are preferred for non-invasive detection of circulating biomarkers such as ctDNA and microRNAs. Proper handling, storage, and processing are essential to preserve molecular integrity. For example, RNA samples require stabilization to prevent degradation, and serum samples must be centrifuged promptly to avoid hemolysis. Advances in liquid biopsy techniques have enabled the detection of tumor-derived molecules in body fluids, expanding access to screening and monitoring. Standardized protocols ensure reproducibility across studies and clinical settings. Sample preparation also includes nucleic acid extraction, protein isolation, and metabolite purification, depending on the biomarker type. This step is foundational for accurate downstream analysis and must be optimized for each biomarker class [52].

7.3. Detection Technologies and Analytical Platforms

Once samples are prepared, various analytical platforms are employed to detect and quantify biomarkers. Next-generation sequencing (NGS) is used for genomic and transcriptomic profiling, identifying mutations, gene fusions, and RNA expression changes. Quantitative PCR (qPCR) and RT-PCR are standard for validating DNA and RNA biomarkers like HPV E6/E7 mRNA. Mass spectrometry (MS) and ELISA are used for proteomic and metabolomic analysis, detecting proteins such as SCC-Ag and CYFRA21-1. Microarrays allow simultaneous analysis of thousands of genes or transcripts. Immunohistochemistry (IHC) visualizes protein expression in tissue samples, useful for markers like p16INK4a and Ki-67. Emerging technologies like biosensors and point-of-care devices offer rapid, low-cost detection, especially in resource-limited settings. Each platform has strengths and limitations in terms of sensitivity, throughput, and cost. Selection depends on the biomarker type, clinical application, and available infrastructure. These technologies form the backbone of biomarker detection and drive innovation in cervical cancer diagnostics [53].

7.4. Bioinformatics and Data Analysis 

High-throughput technologies generate massive datasets that require bioinformatics tools for analysis. Software platforms like STRING, Cytoscape, and GEO2R help identify differentially expressed genes, construct molecular networks, and prioritize biomarker candidates. Functional enrichment analyses (e.g., GO and KEGG) interpret biological significance. Machine learning algorithms such as random forest and support vector machines classify patients and predict outcomes based on biomarker profiles. Integration of multi-omics data enhances predictive accuracy and reveals complex molecular interactions. Bioinformatics also supports reproducibility and cross-study comparisons, making it indispensable in modern cancer research. Data visualization tools aid in presenting findings clearly for clinical translation. As omics data grow, bioinformatics will play an increasingly vital role in biomarker discovery, validation, and implementation. It bridges the gap between raw data and actionable insights, enabling precision medicine in cervical cancer care [54].

7.5. Analytical Validation of Biomarker Assays

Before clinical use, biomarker assays must undergo analytical validation to ensure accuracy, reproducibility, and sensitivity. This involves testing parameters such as limit of detection, specificity, linearity, and precision across different platforms and laboratories. For example, p16INK4a immunostaining must yield consistent results across tissue samples, while qPCR assays for HPV E6/E7 mRNA require standardized primers and controls. Validation also includes assessing robustness under varying conditions (e.g., temperature, reagent batches). Inter-laboratory comparisons and proficiency testing help establish reliability. Regulatory agencies like the FDA require documentation of analytical performance before approving diagnostic tests. Analytical validation is essential to minimize false positives and negatives, ensuring that biomarkers provide trustworthy information. It lays the groundwork for clinical validation and supports integration into routine diagnostics. Without rigorous analytical validation, biomarkers cannot be confidently used to guide patient care [55].

7.6. Clinical Validation and Population Studies

Clinical validation confirms that a biomarker correlates with disease presence, progression, or treatment response in real-world settings. This involves testing in diverse patient populations and comparing biomarker levels with clinical outcomes. For example, methylated DNA markers like SOX1 and EPB41L3 have shown strong associations with CIN2+ lesions. Large-scale studies assess sensitivity, specificity, and predictive value across age groups, ethnicities, and disease stages. Validation also includes longitudinal studies to track biomarker performance over time. Population-based research ensures that biomarkers are applicable across different healthcare settings and demographic profiles. Clinical validation is a critical step before regulatory approval and guideline inclusion. It transforms promising molecular findings into actionable clinical tools, bridging the gap between research and practice. Without robust clinical validation, biomarkers risk being unreliable or non-generalizable [56].

7.7. Regulatory Approval and Standardization

For biomarkers to be used in clinical practice, they must meet regulatory standards set by agencies like the FDA, EMA, or WHO. This includes demonstrating analytical and clinical validity, as well as clinical utility. Regulatory approval involves rigorous documentation, reproducibility across labs, and evidence of improved patient outcomes. Biomarkers like p16/Ki-67 dual staining has undergone such scrutiny and are now used in clinical diagnostics. Standardization of testing protocols, interpretation criteria, and reporting formats is essential for consistent application. Guidelines from professional bodies (e.g., ASCCP) help integrate biomarkers into screening and management algorithms. Regulatory oversight ensures safety, efficacy, and ethical use of biomarker tests. It also facilitates reimbursement and widespread adoption. Without regulatory approval and standardization, biomarkers remain confined to research settings and cannot impact patient care meaningfully [57].

7.8. Clinical Utility and Decision-Making 

Clinical utility refers to a biomarker’s ability to improve patient management decisions. This includes guiding treatment choices, reducing overtreatment, and enhancing screening efficiency. For instance, p16/Ki-67 dual staining helps triage HPV-positive women, minimizing unnecessary colposcopies. Biomarkers like HPV E6/E7 mRNA and methylation panels inform risk stratification and follow-up intervals. Utility assessment involves randomized trials and real-world implementation studies to confirm impact on care pathways. Biomarkers must demonstrate added value over existing methods to justify integration. Clinical utility also includes cost-effectiveness, patient acceptability, and scalability. It ensures that biomarker use translates into better outcomes, not just more data. Without proven utility, even validated biomarkers may fail to gain traction in clinical workflows [58].

7.9. Integration into Guidelines and Practice 

Once validated and approved, biomarkers must be incorporated into clinical guidelines to ensure widespread adoption. Organizations like WHO and ASCCP evaluate evidence and recommend biomarkers for screening and triage. Integration requires consensus on cutoff values, testing protocols, and interpretation standards. For example, HPV E6/E7 mRNA and methylation panels are being considered for inclusion in updated cervical cancer screening algorithms. Guideline inclusion facilitates training, reimbursement, and infrastructure development. It also promotes equity by standardizing care across regions. Biomarkers that enter guidelines become part of routine practice, influencing millions of patient encounters. Without guideline integration, biomarkers risk being underutilized or inconsistently applied [59].

7.10. Real-World Implementation and Monitoring 

The final step is real-world implementation, deploying biomarker tests in routine clinical settings. This includes training personnel, establishing infrastructure, and ensuring supply chain logistics. Pilot programs in low-resource areas have tested point-of-care devices for HPV and methylation markers. Implementation studies assess feasibility, patient acceptability, and health system impact. Continuous monitoring ensures quality control and identifies areas for improvement. Feedback loops help refine protocols and adapt to changing needs. Real-world use also generates data for post-market surveillance and further validation. Successful implementation bridges the gap between innovation and impact, making biomarker-based care accessible and effective [60].

8.1. Improved Early Detection [61]

New biomarkers such as HPV E6/E7 mRNA, DNA methylation markers, and microRNAs offer higher sensitivity and specificity than traditional Pap smears or HPV DNA tests. They help detect precancerous changes earlier, especially in glandular lesions that cytology often misses. This leads to timely intervention and better patient outcomes.

8.2. Enhanced Risk Stratification [62]

Biomarkers allow clinicians to classify patients based on molecular risk rather than relying solely on histology or HPV status. For example, methylation panels and p16/Ki-67 dual staining help identify women at higher risk of progression to CIN2+ or cervical cancer, enabling personalized follow-up strategies.

8.3. Non-Invasive Screening Options [63]

Research has enabled the development of biomarkers detectable in blood, urine, or cervical fluid—such as ctDNA, exosomes, and ACTN4—making screening more accessible and less invasive. This is especially beneficial in low-resource settings or for women reluctant to undergo pelvic exams.

8.4. Better Prognostic Tools [64]

Biomarkers like VEGF, M-CSF, and miR-9 correlate with tumor aggressiveness, recurrence risk, and survival outcomes. Their inclusion in clinical workflows helps predict prognosis more accurately and tailor treatment intensity accordingly.

8.5. Guidance for Targeted Therapies [65]

New biomarkers can identify molecular pathways involved in cervical carcinogenesis, such as SQLE in cholesterol metabolism or PD-L1 in immune evasion. This opens doors for targeted therapies and immunomodulatory treatments, improving therapeutic precision.

8.6. Monitoring Treatment Response [66]

Dynamic biomarkers like ctDNA and circulating microRNAs can be tracked over time to assess treatment efficacy and detect early signs of recurrence. This real-time monitoring supports adaptive therapy and reduces unnecessary interventions.

8.7. Reduction in Overtreatment [67]

Biomarkers improve triage accuracy, helping avoid unnecessary colposcopies or biopsies in HPV-positive women. For instance, p16/Ki-67 dual staining has shown to reduce false positives and streamline care pathways.

8.8. Support for Precision Medicine [68]

Biomarker research enables stratification of patients into molecular subtypes, allowing for individualized screening, diagnosis, and treatment plans. This aligns with the goals of precision oncology and improves overall care quality.

8.9. Integration with AI and Digital Tools [69]

Biomarker datasets can be analyzed using machine learning to uncover hidden patterns and improve diagnostic algorithms. This integration enhances predictive modeling and supports automated decision-making in clinical settings.

8.10. Global Health Impact [70]

New biomarker-based tests—especially those compatible with self-sampling and point-of-care platforms—can expand cervical cancer screening in underserved regions. This helps reduce global disparities in cancer detection and outcomes.

The emergence of novel biomarkers is reshaping cervical cancer care, offering enhanced early detection, personalized treatment, and non-invasive screening. Tools like HPV E6/E7 mRNA, DNA methylation markers, and p16/Ki-67 staining bring greater diagnostic precision, while also enabling better risk stratification and reducing unnecessary interventions. Biomarkers now serve as prognostic indicators, guide targeted therapies, and support real-time monitoring of treatment response. Their fusion with AI and digital platforms elevates diagnostic workflows and expands access to underserved regions—accelerating progress toward global health equity. Continued investment in biomarker research not only refines clinical accuracy but also builds the foundation for scalable, cost-effective screening programs. This is especially vital for developing countries where resources are limited but the burden of disease is high. As research continues to unveil new molecular targets, these innovations pave the way for a future that is more predictive, personalized, and preventative in cervical oncology.